Agile Therapeutics reports Q4 EPS ($1.51) vs (10c) last year

Reports Q4 revenue $3.615M vs $3.996M last year. “2023 was a year for Agile that we believe demonstrated our ability to continue to grow Twirla,” said Agile Therapeutics Chairperson and Chief Executive Officer Al Altomari. “We believe we answered questions about our business model’s sustainability in 2023 by once again demonstrating meaningful year-over-year growth in net revenue, Twirla demand, and Twirla factory sales while simultaneously keeping operating expenses at responsible levels. We continue to believe in our business model with an emphasis on partnerships to maximize Twirla’s growth potential. We will continue to explore any and all strategic opportunities, both internally and externally, that have the ability to maximize Twirla growth and increase shareholder value.”